503Bs, 503As, and Panic

People should not panic over the ProRx situation. I know, it sucks for those who like them, but there are other pharmacies and it's not the end of GLP compounding.

ProRx is a 503B, and 503Bs have always had much less room to operate than 503As when it comes to individualized compounded GLP meds. A lot of people have been expecting FDA pressure on 503Bs that were pushing right up against 503A-type activity. That is not exactly new, and it is part of why other 503Bs like Olympia backed off earlier. Everyone knew this is why Olympia stopped, and many of us were surprised when ProRx decided to keep going and when BPI started back up.

A 503B getting hit does not automatically mean 503As are about to disappear. They operate under a different framework. So long as they continue operating within that framework, they will be fine.

I know there are a lot of newer people here, but last summer, we all expected 503Bs to stop and for 503As to continue. We're finally catching up to that reality. But it's *not* the end.